ArticleAging2020
Cardamonin induces G2/M phase arrest and apoptosis through inhibition of NF-κB and mTOR pathways in ovarian cancer.
Article in Aging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- The Bidirectional Role of Cellular Senescence in the Treatment of Ovarian Cancer.Biomedicines · 2026Review
- The role of cytokines in ovarian cancer drug resistance.International journal of cancer · 2026Review
- A Multidimensional Perspective Review of Traditional Chinese Medicine in Treating Ovarian Aging.International journal of women's health · 2026Review
- Cardamonin attenuates angiotensin II-induced abdominal aortic aneurysms through activation of the Nrf2/HO-1 pathway.International journal of cardiology. Heart & vasculature · 2025Article
- Cardamonin as a potential anticancer agent: Preclinical insights and clinical implications.World journal of clinical oncology · 2025Review
- Cardamonin Inhibits the Nuclear Translocation and DNA Binding of RelA in the Tumor Necrosis Factor-α-Induced NF-κB Signaling Pathway in Human Lung Adenocarcinoma A549 Cells.Molecules (Basel, Switzerland) · 2025Article
- Cardamom synergizes with cisplatin against human osteosarcoma cells by mTOR-mediated autophagy.Cancer gene therapy · 2025Article
- Pulsed cavitation ultrasound assisted delivery of cardamom, pistacia and laurel encapsulated micelles nanoparticles for sono-photodynamic lymphoma in vitro and in vivo treatment.Lasers in medical science · 2025Article
- SLC7A5 regulates tryptophan uptake and PD‑L1 expression levels via the kynurenine pathway in ovarian cancer.Oncology letters · 2025Article
- Medicinally Privileged Natural Chalcones: Abundance, Mechanisms of Action, and Clinical Trials.International journal of molecular sciences · 2024Review
- Targeting STAT3 and NF-κB Signaling Pathways in Cancer Prevention and Treatment: The Role of Chalcones.Cancers · 2024Review
- Hydroxysafflor yellow A: a natural pigment with potential anticancer therapeutic effect.Frontiers in pharmacology · 2024Review
- Article
- Regulated cell death (RCD) in cancer: key pathways and targeted therapies.Signal transduction and targeted therapy · 2022Review
- Cardamonin inhibits the expression of P-glycoprotein and enhances the anti-proliferation of paclitaxel on SKOV3-Taxol cells.Journal of natural medicines · 2022Article
- Chalcone Derivatives: Role in Anticancer Therapy.Biomolecules · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardamonin, a natural chalcone, is reported to induce apoptosis and inhibit cancer cell growth. However, the mechanisms underlying the therapeutic effects of cardamonin remain to be established. Here, we have focused on cardamonin-induced apoptosis in ovarian cancer cells, both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.